Scientists at the University of California, San Francisco have built an immune-cell therapy that switches itself on only inside the brain — and in laboratory tests it wiped out one of the deadliest childhood cancers in every mouse treated. The treatment, called B-SYNC CAR-T therapy, cleared diffuse midline glioma in 10 of 10 mice in one human tumour model and 9 of 9 in a second, while conventional CAR-T cells failed. The results, published on October 28 in Science Translational Medicine, have put the team on course for a first human trial that could open as early as April 2027.

Key Points

• B-SYNC cleared diffuse midline glioma in every mouse treated — 10 of 10 in one model, 9 of 9 in another — when delivered into the brain's ventricles.
• The cells stay switched off in the body and activate only after sensing brevican, a protein found throughout the brain.
• By IV drip, it shrank tumours in roughly a third to nearly half of the mice.
• Treated mice were still protected after 70 days, and every one rejected a second tumour challenge seven weeks later.
• A first human trial could open in April 2027 in children and young adults, though the results are still preclinical.

What Happened

The study, led by neurosurgeon-scientist Hideho Okada and synthetic biologist Wendell Lim, tested B-SYNC against diffuse midline glioma (DMG), one of the most feared diagnoses in children's cancer medicine. Researcher Senthilnath Lakshmanachetty first gave the engineered cells by IV drip to mice carrying human DMG cells. Some crossed into the brain, switched on their cancer-fighting receptors and shrank tumours in roughly a third to nearly half of the animals — while cells in the blood and spleen stayed switched off, confirming activation was limited to the brain. Delivered into the brain's ventricles, it then cleared every tumour: 10 of 10 mice in one model and 9 of 9 in the other, while conventional CAR-T cells failed. Seven weeks later, every treated mouse also rejected a fresh batch of DMG cells, and the cells were still patrolling for cancer after 70 days.

Background: A Cancer That Defies Treatment

DMG infiltrates healthy brain tissue, often growing in the brainstem, which controls breathing, heart rate and swallowing — so surgery is usually impossible, and children diagnosed with it almost always die within a year. CAR-T therapy has transformed some blood cancers but has not controlled solid brain tumours: the cells fail to reach the tumour or cause side effects when always switched on. B-SYNC builds on an earlier UCSF treatment, E-SYNC (2021), which used the same sensor to detect EGFRvIII — but only about 20 percent of glioblastoma patients carry that marker. Brevican, found throughout the brain, is a far broader trigger, and DMG cells frequently carry the EphA2 and IL13Rα2 proteins the activated cells attack.

How B-SYNC CAR-T Therapy Works

B-SYNC's T cells carry a synthetic sensor called synNotch that detects brevican and only then triggers production of cancer-targeting receptors, known as CARs, which attack cells carrying EphA2 or IL13Rα2. It is a two-step lock: first the cell must sense it is in the brain, and only then does it arm itself. Keeping the cells quiet until they arrive may also stop them becoming exhausted, though the researchers have not yet proved that mechanism. That precision is what cleared every tumour in the mouse experiments where standard, always-on CAR-T cells failed.

Reactions and Quotes

"It's been a struggle to make CAR-T cells that overcome DMG without causing unacceptable side effects," said Hideho Okada, a UCSF professor of neurological surgery. "By limiting B-SYNC's CAR expression to when and where it matters — in the brain — we saw consistent, total shutdown of DMG tumors in the lab." Lakshmanachetty said the brain-only activation worked exactly as intended — cells in the blood and spleen stayed switched off, "just as we designed it" — and called the durability a surprise: "We didn't expect B-SYNC CAR-T cells to necessarily persist. But they are still patrolling for cancer over 70 days out — and they're still very functional."

Sabine Mueller, director of the UCSF Pediatric Brain Tumor Center, called the data "very promising": "Mice with DMG are being cured, and we are incredibly excited to bring this therapy to the children and young adults we care for." The researchers stress the limits: all results are preclinical, and one alternate version of the therapy caused fatal neurotoxicity in mice.

Why It Matters

For families, DMG is one of the cruellest diagnoses in medicine: a cancer of young children in a part of the brain surgeons cannot reach, with no treatment that reliably extends life beyond a year. The design is also a platform, not a one-off drug: the same synNotch switch could in principle target other brain tumours carrying EphA2 or IL13Rα2, including some adult glioblastomas. Backed by the National Institutes of Health, it went from October publication to a possible April 2027 trial in barely five months.

What Happens Next

The first human study, potentially beginning in April 2027 at UCSF Health, will test B-SYNC in children and young adults with brain tumours, led by Marie Jaeger-Krause and Sabine Mueller. Each patient's own T cells will be modified and returned, and the trial will compare intravenous and ventricle delivery; patients receiving direct brain delivery will get an implanted shunt connected to a reservoir under the scalp for repeated treatments. The trial's first job will be to establish whether B-SYNC is safe — mouse results do not guarantee the same outcome in people. April 2027 is a target, not a promise.

Frequently Asked Questions

What is B-SYNC CAR-T therapy?

An experimental UCSF immune-cell therapy: a patient's T cells are engineered with a synNotch sensor that detects brevican, a protein found throughout the brain. Only then do the cells produce receptors that attack tumour cells carrying EphA2 or IL13Rα2.

What is diffuse midline glioma?

An aggressive childhood brain cancer that infiltrates the brainstem, which controls breathing, heart rate and swallowing. It includes the subset once called DIPG, surgery is usually impossible, and children diagnosed with it almost always die within a year.

How well did it work in mice?

Delivered into the brain's ventricles, B-SYNC cleared every tumour — 10 of 10 in one human tumour model and 9 of 9 in another — while conventional CAR-T cells failed. By IV drip, it shrank tumours in roughly a third to nearly half of the mice, and treated mice rejected a second tumour challenge seven weeks later.

When will it be tested in people?

The UCSF team is preparing a first human trial that could open as early as April 2027, in children and young adults with brain tumours, led by Marie Jaeger-Krause and Sabine Mueller.

Is the therapy safe?

Not yet known. All results so far are from mice, and one alternate version caused fatal neurotoxicity in animals. The planned trial will first establish whether B-SYNC is safe in people.

Related coverage: FDA Investigates Zolgensma Tumour Risk in Children After Gene Therapy Link | AMA Clinical AI Liability Framework: Who Pays When Medical AI Harms Patients | Artemis III Crew Meets Trump at White House Before 2027 Moon Mission Tests